Full Text View
Tabular View
No Study Results Posted
Related Studies
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) (Xolair)
This study has been completed.
Study NCT00367016   Information provided by University of California, Davis
First Received: August 19, 2006   Last Updated: May 7, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
Allergic Rhinitis
Atopic Dermatitis
Additional conditions recognized in this trial
Dermatitis
Dermatitis, Atopic
Rhinitis
More general conditions related to this trial
Bronchial Diseases
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Interventions listed in this trial
Xolair (Omalizumab)
Placebo
Additional drug interventions recognized in this trial
Omalizumab
More general drug interventions related to this trial
Anti-Allergic Agents
Anti-Asthmatic Agents
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
University of California, Davis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services